Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "continuity-of-care"

25 News Found

India chairs first BRICS Health Working Group meet
Policy | April 16, 2026

India chairs first BRICS Health Working Group meet

Outlines nine priority health tracks spanning TB research, digital health, early warning systems and regulatory cooperation


Pinky Promise opens first physical clinic in Mumbai, expands women’s hybrid healthcare model
Healthcare | April 15, 2026

Pinky Promise opens first physical clinic in Mumbai, expands women’s hybrid healthcare model

AI-enabled women’s digital clinic brings in-person consultations to complement app-led care after serving over 400,000 women across India


Why secure, empathetic home care defines the next era of healthcare delivery: Suhasini Deshmukh, Co-founder, MedRabbits
Opinion | April 14, 2026

Why secure, empathetic home care defines the next era of healthcare delivery: Suhasini Deshmukh, Co-founder, MedRabbits

Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs


NATCO announces launch of Pomalidomide capsules in US
News | March 05, 2026

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma


Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
News | February 09, 2026

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution


Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays
News | December 21, 2025

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays

The initiative is focused on a problem that continues to plague cancer outcomes in India


EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
Clinical Trials | October 31, 2025

EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours

Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1


AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
Drug Approval | September 24, 2025

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population